Oxana Beskrovnaya

Company: Dyne Therapeutics

Job title: Chief Scientific Officer

Seminars:

DYNE-101 & DYNE-251: Moving From Bench to Clinic to Deliver Potentially Transformative Therapies in DM1 & DMD 9:00 am

Sharing how the FORCETM platform harnesses the natural expression of transferrin receptor 1 (TfR1) on muscle cells for targeted delivery of rationally selected payload with the goal of addressing the underlying causes of rare and genetic muscle diseases Discussing robust data using multiple preclinical models to validate the two lead FORCE conjugates, DYNE-101 and DYNE-251…Read more

day: Scientific Program Day One